Crohn's Disease and Ulcerative Colitis Insurance Denied: How to Appeal

Inflammatory bowel disease (IBD) — encompassing Crohn's disease and ulcerative colitis — is a chronic, potentially life-threatening autoimmune condition that requires ongoing and often expensive medical management. The treatments that work best — biologic infusions, immunomodulators, and sometimes surgery — are also the ones most frequently denied by insurance companies. If your IBD treatment has been denied, here is how to build an effective appeal.

What Gets Denied in IBD Treatment

Biologic Infusions and Injections: Biologics like infliximab (Remicade, Inflectra), adalimumab (Humira), vedolizumab (Entyvio), ustekinumab (Stelara), and risankizumab (Skyrizi) are FDA-approved for Crohn's disease and/or ulcerative colitis. These medications require Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization and face several types of denial:

• Step therapy ("fail-first"): Requiring failure of 5-ASA agents, corticosteroids, and immunomodulators (azathioprine, methotrexate) before approving a biologic, even when early biologic therapy is clinically indicated to prevent disease progression
• Non-preferred biologic: Requiring the patient to try a biosimilar or different biologic in the same class before approving the prescribed medication
• Site of service denials: Approving the drug but denying infusion center or hospital outpatient administration, requiring home infusion in circumstances where clinical monitoring makes infusion center administration necessary

Colonoscopy Frequency: IBD patients require colonoscopic surveillance more frequently than the general population — for disease activity monitoring, dysplasia surveillance, and adjusting treatment. Insurers may deny surveillance colonoscopies as exceeding frequency guidelines designed for average-risk colorectal cancer screening, which are not applicable to IBD.

Hospitalization for Flares: Acute IBD flares requiring inpatient management may face concurrent review denials, with insurers attempting to discharge patients before clinical stability is achieved. These denials carry particular risk given the potential for perforation, toxic megacolon, or sepsis.

Surgical Resection: Colectomy or bowel resection — necessary when medical management fails or complications arise — may face prior authorization denials requiring demonstration of failed medical therapy, second surgical opinions, or designation of specific surgical facilities.

Combination Therapy: The combination of a biologic plus an immunomodulator (e.g., infliximab + azathioprine) is supported by clinical evidence (SONIC trial for Crohn's) but may be denied by insurers who will only cover one agent at a time.

Clinical Evidence for IBD Appeals

For biologic step therapy overrides:

• AGA (American Gastroenterological Association) Clinical Guidelines and ACG Practice Guidelines support early biologic therapy in moderate-to-severe IBD and in patients with poor prognostic features (penetrating disease, perianal involvement, extensive disease, prior steroid dependence)
• Document the specific clinical features that make early biologic therapy appropriate per guideline criteria
• If step therapy drugs were previously tried, document the trials exhaustively: drug, dose, duration, outcomes, adverse effects

For colonoscopy frequency:

• ACG and ASGE guidelines recommend surveillance colonoscopy every 1–2 years for IBD patients with long-standing colitis, and more frequently in patients with primary sclerosing cholangitis
• Your gastroenterologist should document the IBD-specific rationale distinguishing your need from general population screening schedules

For combination therapy:

• Cite the SONIC trial and subsequent data supporting combination therapy for reducing immunogenicity and improving remission rates
• Document anti-drug antibody development or subtherapeutic drug levels if available (therapeutic drug monitoring data)

Step Therapy Overrides for Biologics

Many states have enacted step therapy override laws. Under these laws, your prescribing gastroenterologist can request a step therapy exception by documenting one or more of the following:

1. The required first-step drug is contraindicated
2. The required first-step drug was previously tried and failed
3. The required drug would cause adverse reactions given the patient's comorbidities or other medications
4. The prescribed biologic is clinically superior for this specific patient based on documented clinical factors

Submit the step therapy exception request with your physician's clinical documentation before or simultaneous with the initial prior authorization request, not after a denial.

Hospital Denials and Concurrent Review

If your hospitalization is being denied or days are being cut during an active admission, the treatment team must act quickly. The utilization review nurse or physician at your hospital can request an emergency peer-to-peer review with the insurer's medical director. For Crohn's or UC patients admitted for severe flares, continued inpatient care during instability is clinically defensible and legally protected — document vitals, lab trends, and clinical status carefully throughout admission.

Fight Back With ClaimBack

IBD is a serious, lifelong condition. The treatments that control it are expensive but necessary — and you have legal rights to access them through your insurance. ClaimBack helps IBD patients build the clinical and legal case to overturn denials.

Start your Crohn's disease or ulcerative colitis insurance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter That Gets Results
• What Is Medical Necessity — and How to Prove It to Your Insurer
• Internal vs. External Insurance Appeals: Which Path Is Right for You?